Straits Times Index
3,302.79 +9.86 (+0.30%) Nikkei
38,236.07 -38.03 (-0.10%) Hang Seng
18,476.99 +1.07 (+0.01%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
64,177.40 +981.92 (+1.55%) CMC Crypto 200
1,337.17 +24.54 (+1.87%)
Gilead Sciences, Inc. (GILD.VI)
| Previous close | 60.93 |
| Open | 60.81 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 59.86 - 60.81 |
| 52-week range | 59.86 - 79.86 |
| Volume | |
| Avg. volume | 6 |
| Market cap | 75.286B |
| Beta (5Y monthly) | 0.20 |
| PE ratio (TTM) | 176.06 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.88 (4.81%) |
| Ex-dividend date | 14 Jun 2024 |
| 1y target est | N/A |
- Business Wire
Gilead Sciences to Present at Upcoming Investor Conferences
FOSTER CITY, Calif., April 30, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:
- Business Wire
FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV
FOSTER CITY, Calif., April 26, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to treat pregnant people with HIV-1 (PWH) with suppressed viral loads. These additional data stem from Study 5310, which evaluated the pharmacokinetics, safety and efficacy of
- Business Wire
Gilead Sciences Announces First Quarter 2024 Financial Results
FOSTER CITY, Calif., April 25, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2024 results of operations.
